SEC 13F Intelligence

Slate Path Capital LP / ALNY

Slate Path Capital LP’s Alnylam Pharmaceuticals Inc Position

Does Slate Path Capital LP own Alnylam Pharmaceuticals Inc (ALNY)? Not currently — the last reported position was 213.0K shares worth $31M in Q3 2020; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$31M
Q3 2020
Shares
213.0K
% of Portfolio
+1.76%
Quarters Held
8
position exited

Position History ALNY

Reported value by quarter
Q4 ’18: $35MQ4 ’18Q1 ’19: $45MQ1 ’19Q2 ’19: $45MQ2 ’19Q3 ’19: $49MQ3 ’19Q4 ’19: $94MQ4 ’19Q1 ’20: $78MQ1 ’20Q2 ’20: $86MQ2 ’20Q3 ’20: $31MQ3 ’20filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2020213.0K$31M+1.76%
Q2 2020584.0K$86M+5.10%
Q1 2020718.0K$78M+5.99%
Q4 2019815.0K$94M+5.06%
Q3 2019615.0K$49M+3.27%
Q2 2019615.0K$45M+2.00%
Q1 2019480.0K$45M+3.63%
Q4 2018480.0K$35M+3.94%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Slate Path Capital LP’s full portfolio or all institutional holders of ALNY.